US Stock MarketDetailed Quotes

Monopar Therapeutics (MNPR)

Watchlist
  • 56.080
  • -1.840-3.18%
Close Apr 10 16:00 ET
  • 56.080
  • 0.0000.00%
Post 16:10 ET
375.30MMarket Cap-30.31P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Monopar Therapeutics (MNPR) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2025
(Q4)Dec 31, 2025
(Q3)Sep 30, 2025
(Q2)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
3.36%16.7M
-44.42%6.16M
159.89%4.09M
80.81%3.23M
86.95%3.22M
83.01%16.16M
479.22%11.07M
-23.77%1.57M
-23.17%1.79M
-31.75%1.72M
Selling and administrative expenses
115.49%6.8M
92.53%2.21M
154.53%1.5M
128.68%1.5M
108.44%1.58M
-2.33%3.16M
31.22%1.15M
-21.19%590.62K
-10.32%657.81K
-13.12%757.28K
-General and administrative expense
115.49%6.8M
92.53%2.21M
154.53%1.5M
128.68%1.5M
108.44%1.58M
-2.33%3.16M
31.22%1.15M
-21.19%590.62K
-10.32%657.81K
-13.12%757.28K
Research and development costs
-23.85%9.9M
-60.29%3.94M
163.11%2.59M
52.96%1.73M
70.10%1.64M
132.24%13.01M
858.35%9.92M
-25.24%984.28K
-29.08%1.13M
-41.57%966.11K
Operating profit
-3.36%-16.7M
44.42%-6.16M
-159.89%-4.09M
-80.81%-3.23M
-86.95%-3.22M
-83.01%-16.16M
-479.22%-11.07M
23.77%-1.57M
23.17%-1.79M
31.75%-1.72M
Net non-operating interest income expense
639.45%2.99M
540.41%954.43K
559.80%655.47K
962.63%780.77K
626.40%596.85K
-5.83%404.02K
51.96%149.04K
-11.51%99.34K
-42.70%73.48K
-9.20%82.17K
Non-operating interest income
639.45%2.99M
540.41%954.43K
559.80%655.47K
962.63%780.77K
626.40%596.85K
-5.83%404.02K
51.96%149.04K
-11.51%99.34K
-42.70%73.48K
-9.20%82.17K
Other net income (expense)
171.28K
0
171.28K
Other non- operating income (expenses)
----
----
----
----
----
--171.28K
--0
--171.28K
----
----
Income before tax
11.99%-13.72M
52.40%-5.2M
-163.56%-3.44M
-43.04%-2.45M
-59.94%-2.62M
-85.50%-15.59M
-502.32%-10.93M
33.24%-1.3M
22.03%-1.72M
32.59%-1.64M
Income tax
Net income
11.99%-13.72M
52.40%-5.2M
-163.56%-3.44M
-43.04%-2.45M
-59.94%-2.62M
-85.50%-15.59M
-502.32%-10.93M
33.24%-1.3M
22.03%-1.72M
32.59%-1.64M
Net income continuous Operations
11.99%-13.72M
52.40%-5.2M
-163.56%-3.44M
-43.04%-2.45M
-59.94%-2.62M
-85.50%-15.59M
-502.32%-10.93M
33.24%-1.3M
22.03%-1.72M
32.59%-1.64M
Minority interest income
Net income attributable to the parent company
11.99%-13.72M
52.40%-5.2M
-163.56%-3.44M
-43.04%-2.45M
-59.94%-2.62M
-85.50%-15.59M
-502.32%-10.93M
33.24%-1.3M
22.03%-1.72M
32.59%-1.64M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
11.99%-13.72M
52.40%-5.2M
-163.56%-3.44M
-43.04%-2.45M
-59.94%-2.62M
-85.50%-15.59M
-502.32%-10.93M
33.24%-1.3M
22.03%-1.72M
32.59%-1.64M
Basic earnings per share
54.99%-1.85
76.73%-0.64
-29.73%-0.48
28.57%-0.35
25.49%-0.38
-35.20%-4.11
-350.82%-2.75
46.38%-0.37
38.75%-0.49
46.32%-0.51
Diluted earnings per share
54.99%-1.85
76.73%-0.64
-29.73%-0.48
28.57%-0.35
25.49%-0.38
-35.20%-4.11
-350.82%-2.75
46.38%-0.37
38.75%-0.49
46.32%-0.51
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit Opinions
Unqualified Opinion with Explanatory Notes
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2025(Q4)Dec 31, 2025(Q3)Sep 30, 2025(Q2)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 3.36%16.7M-44.42%6.16M159.89%4.09M80.81%3.23M86.95%3.22M83.01%16.16M479.22%11.07M-23.77%1.57M-23.17%1.79M-31.75%1.72M
Selling and administrative expenses 115.49%6.8M92.53%2.21M154.53%1.5M128.68%1.5M108.44%1.58M-2.33%3.16M31.22%1.15M-21.19%590.62K-10.32%657.81K-13.12%757.28K
-General and administrative expense 115.49%6.8M92.53%2.21M154.53%1.5M128.68%1.5M108.44%1.58M-2.33%3.16M31.22%1.15M-21.19%590.62K-10.32%657.81K-13.12%757.28K
Research and development costs -23.85%9.9M-60.29%3.94M163.11%2.59M52.96%1.73M70.10%1.64M132.24%13.01M858.35%9.92M-25.24%984.28K-29.08%1.13M-41.57%966.11K
Operating profit -3.36%-16.7M44.42%-6.16M-159.89%-4.09M-80.81%-3.23M-86.95%-3.22M-83.01%-16.16M-479.22%-11.07M23.77%-1.57M23.17%-1.79M31.75%-1.72M
Net non-operating interest income expense 639.45%2.99M540.41%954.43K559.80%655.47K962.63%780.77K626.40%596.85K-5.83%404.02K51.96%149.04K-11.51%99.34K-42.70%73.48K-9.20%82.17K
Non-operating interest income 639.45%2.99M540.41%954.43K559.80%655.47K962.63%780.77K626.40%596.85K-5.83%404.02K51.96%149.04K-11.51%99.34K-42.70%73.48K-9.20%82.17K
Other net income (expense) 171.28K0171.28K
Other non- operating income (expenses) ----------------------171.28K--0--171.28K--------
Income before tax 11.99%-13.72M52.40%-5.2M-163.56%-3.44M-43.04%-2.45M-59.94%-2.62M-85.50%-15.59M-502.32%-10.93M33.24%-1.3M22.03%-1.72M32.59%-1.64M
Income tax
Net income 11.99%-13.72M52.40%-5.2M-163.56%-3.44M-43.04%-2.45M-59.94%-2.62M-85.50%-15.59M-502.32%-10.93M33.24%-1.3M22.03%-1.72M32.59%-1.64M
Net income continuous Operations 11.99%-13.72M52.40%-5.2M-163.56%-3.44M-43.04%-2.45M-59.94%-2.62M-85.50%-15.59M-502.32%-10.93M33.24%-1.3M22.03%-1.72M32.59%-1.64M
Minority interest income
Net income attributable to the parent company 11.99%-13.72M52.40%-5.2M-163.56%-3.44M-43.04%-2.45M-59.94%-2.62M-85.50%-15.59M-502.32%-10.93M33.24%-1.3M22.03%-1.72M32.59%-1.64M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 11.99%-13.72M52.40%-5.2M-163.56%-3.44M-43.04%-2.45M-59.94%-2.62M-85.50%-15.59M-502.32%-10.93M33.24%-1.3M22.03%-1.72M32.59%-1.64M
Basic earnings per share 54.99%-1.8576.73%-0.64-29.73%-0.4828.57%-0.3525.49%-0.38-35.20%-4.11-350.82%-2.7546.38%-0.3738.75%-0.4946.32%-0.51
Diluted earnings per share 54.99%-1.8576.73%-0.64-29.73%-0.4828.57%-0.3525.49%-0.38-35.20%-4.11-350.82%-2.7546.38%-0.3738.75%-0.4946.32%-0.51
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Audit Opinions Unqualified Opinion with Explanatory Notes--------Unqualified Opinion--------
Market Insights
No. Symbol 20D % Chg
Sample Name
Sample Code
 +10.02%
Sample Name
Sample Code
 +5.43%
Sample Name
Sample Code
 +2.46%
4
SPDR S&P Oil & Gas Exploration & Production ETF
XOP
+1.46%
5
United Sts 12 Month Oil Fd Lp Unit Ben Int
USL
+0.70%
View More
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +12.34%
Sample Name
Sample Code
 +11.49%
Sample Name
Sample Code
 +10.29%
4
Futu Holdings Ltd
FUTU
+10.23%
5
Hesai
HSAI
+9.84%
View More
Middle East conflict spreads to the stock market! How should investors respond?
On April 12 local time, U.S. Vice President Vance stated that negotiations between the United States and Iran failed to reach an agreement, Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -